Longitudinal Clinical Outcomes After Intra‐Articular Dexamethasone–Lidocaine Injection for Temporomandibular Joint Arthralgia
Journal of Oral Rehabilitation · 20.11.2026
DOI: 10.1111/joor.70347 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Oral Rehabilitation, online erschienen am 20.11.2026. Verfasst von Yeon‐Hee Lee und 2 weiteren Autor:innen. Die Arbeit nennt 43 Literaturangaben.
Abstract (Originalsprache)
Background
Longitudinal real‐world data on intra‐articular dexamethasone–lidocaine injection for temporomandibular joint ( TMJ ) arthralgia remain limited. This study evaluated post‐injection clinical trajectories in patients with TMJ arthralgia.
Methods
This retrospective observational study included 191 patients (45.5 ± 20.7 years; 67.5% female) with TMJ arthralgia who received intra‐articular dexamethasone–lidocaine injection. Mean follow‐up from baseline injection to the last available follow‐up was 77.0 ± 82.7 days. Outcomes included visual analogue scale ( VAS ), comfortable mouth opening ( CMO ), maximum mouth opening ( MMO ), pain presence, and pain‐location burden. Paired, longitudinal, and final‐outcome analyses were performed, with additional exploratory analyses.
Results
At first follow‐up, VAS decreased from 3.25 ± 1.75 to 2.45 ± 1.67 (change, −0.80 ± 1.44; FDR ‐adjusted p < 0.001), CMO increased modestly by 0.99 ± 5.98 mm ( FDR ‐adjusted p = 0.015), and pain‐location burden decreased by 0.30 ± 0.90 ( FDR ‐adjusted p < 0.001). MMO did not change significantly ( FDR ‐adjusted p = 0.166). Mixed‐effects models using actual elapsed time showed decreases in VAS ( β = −0.069 per 30 days; FDR ‐adjusted p = 0.003) and pain‐location burden ( β = −0.093 per 30 days; FDR ‐adjusted p < 0.001) and a modest increase in CMO ( β = 0.343 mm per 30 days; FDR ‐adjusted p = 0.001), whereas MMO showed no significant longitudinal change. The absolute VAS decrease was greater in the moderate‐to‐severe baseline pain group than in the mild pain group (−1.68 ± 1.56 vs. −0.35 ± 1.13; FDR ‐adjusted p < 0.001). At final follow‐up, VAS had decreased from baseline in 53.4% of patients, including 80.0% of those with moderate‐to‐severe baseline pain ( FDR ‐adjusted p < 0.001).
Conclusions
Intra‐articular dexamethasone–lidocaine injection was followed by decreases in pain intensity and pain‐location burden and a modest increase in CMO , whereas MMO showed no consistent longitudinal change. These findings support a multidomain approach to assessing clinical trajectories after TMJ injection.
Zitieren
APA
Lee, Y., Kim, T., & Noh, Y. (2026). Longitudinal Clinical Outcomes After Intra‐Articular Dexamethasone–Lidocaine Injection for Temporomandibular Joint Arthralgia. Journal of Oral Rehabilitation. https://doi.org/10.1111/joor.70347
Vancouver
Lee Y, Kim T, Noh Y. Longitudinal Clinical Outcomes After Intra‐Articular Dexamethasone–Lidocaine Injection for Temporomandibular Joint Arthralgia. Journal of Oral Rehabilitation. 2026. doi:10.1111/joor.70347
BibTeX
@article{Lee2026,
author = {Lee, Yeon‐Hee and Kim, Tae‐Seok and Noh, Yung‐Kyun},
title = {Longitudinal Clinical Outcomes After Intra‐Articular Dexamethasone–Lidocaine Injection for Temporomandibular Joint Arthralgia},
journal = {Journal of Oral Rehabilitation},
year = {2026},
doi = {10.1111/joor.70347}
}
EUVIMED